SOURCE-LINKED STUDY SUMMARY
Semaglutide and Papillary Thyroid Carcinoma: Current Evidence on Risk, Progression, and Mechanisms
Abstract summarizedQuality not appraised
- What was studied
- A narrative review examined semaglutide and papillary thyroid cancer, including cancer development, progression and laboratory mechanisms.
- Who / model studied
- Evidence included 93 trials with 101,732 participants and a cohort of 1072 people with existing differentiated thyroid cancer, followed for a median 69 months.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The reviewed trials showed no statistically clear increase in thyroid-cancer risk. The existing-cancer cohort found no association with structural progression. Other observational and adverse-report analyses raised risk signals.
- Limitations & context
- Detection bias and obesity-related confounding affect the risk signals. Further prospective research specific to cancer subtype is needed.
Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.20944/preprints202609.0561.v1